Heart failure & cardiomyopathies
Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure
Authors' conclusion
This randomized prospective trial revealed the addition of DAPA within 24 h after admission reduced the diuretic dose without WRF.
Study context
- Population
- Acute decompensated heart failure (ADHF) patients with a left ventricular ejection fraction (LVEF) of less than 50%consecutive ADHF patients enrolled
- Participants
- 114 participants
- Comparison
- adding dapagliflozin (DAPA) as compared to standard decongestive therapy with loop diuretics alone
- Primary endpoint
- Incidence of worsening renal function (WRF) (increase in the serum creatinine of ≥0.3 mg/dL from baseline)
Primary result
As reported in the abstract
P = 0.54
Further findings
Total dose of loop diuretics · through day 7 · lower in the DAPA group
P = 0.03
Baseline characteristics
- Median age (years) [IQR]
- 77 [interquartile range (IQR): 64, 85]
- Female
- 35%
- Median LVEF (%) [IQR]
- 33 [IQR: 28, 38]
Original publication
Randomized Trial to Assess Worsening Renal Function By Adding Dapagliflozin for Acute Decompensated Heart Failure. ESC Heart Fail. Published 31 January 2025. doi:10.
Summarised from the published abstract; every number is checked against it